Association of the COVID-19 Outbreak With Patient Willingness to Enroll in Cancer Clinical Trials
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
The coronavirus disease 2019 (COVID-19) outbreak substantially reduced cancer clinical trial accrual.1 Many sites temporarily paused enrollment owing to state, local, sponsor, or institutional restrictions intended to prevent the spread of COVID-19.2 Once site and enrollment restrictions lift, it is unclear whether patients will be as willing to participate in clinical research as before the outbreak, especially if community COVID-19 transmission is still occurring. To examine this, we surveyed a large group of cancer survivors about their attitudes toward trial participation during the COVID-19 pandemic.
JAMA Oncology , résumé, 2019